| Name | Metro Prosthetics |
|---|---|
| Organization Name | Metro Prosthetics, Inc. |
| Location | 4320 Fitch Ave, Nottingham, Maryland 21236 |
| Type | Prosthetic/Orthotic Supplier |
| Phone | (410) 870-0365 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Clementia Pharmaceuticals, Inc. announced today the initiation of a Phase 2 extension study of palovarotene in patients with fibrodysplasia ossificans progressiva (FOP), a rare, severely disabling genetic disease characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) and new abnormal bone formation.
Current industry practices for large-scale mammalian cell cultures typically employ a standard platform fed-batch process with fixed volume bolus feeding. Although widely used, these processes are unable to respond to actual nutrient consumption demands from the culture, which can result in accumulation of by-products and depletion of certain nutrients.
ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, today announced that it will be presenting today, at the Annual Meeting of the Congress of Neurological Surgeons in New Orleans, Louisiana at 3:15pm central time, data from its Phase I clinical trial investigating the role that its ICT-107 vaccine may play in increasing patient survival and inhibiting tumor progression in patients with glioblastoma, the most common and most aggressive type of primary brain tumor.
Last week, at the Society for Neuroscience Conference in Washington DC, Neuronetrix announced preliminary results from a clinical study of their COGNISION System to diagnose Alzheimer's disease.
› Verified 1 days ago
| NPI Number | 1316216393 |
| Organization Name | METRO PROSTHETICS, INC. |
| Type | Prosthetic/Orthotic Supplier |
| Address | 4320 Fitch Ave, Nottingham, MD 21236 |
| Phone Number | 410-870-0365 |
News Archive
Clementia Pharmaceuticals, Inc. announced today the initiation of a Phase 2 extension study of palovarotene in patients with fibrodysplasia ossificans progressiva (FOP), a rare, severely disabling genetic disease characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) and new abnormal bone formation.
Current industry practices for large-scale mammalian cell cultures typically employ a standard platform fed-batch process with fixed volume bolus feeding. Although widely used, these processes are unable to respond to actual nutrient consumption demands from the culture, which can result in accumulation of by-products and depletion of certain nutrients.
ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, today announced that it will be presenting today, at the Annual Meeting of the Congress of Neurological Surgeons in New Orleans, Louisiana at 3:15pm central time, data from its Phase I clinical trial investigating the role that its ICT-107 vaccine may play in increasing patient survival and inhibiting tumor progression in patients with glioblastoma, the most common and most aggressive type of primary brain tumor.
Last week, at the Society for Neuroscience Conference in Washington DC, Neuronetrix announced preliminary results from a clinical study of their COGNISION System to diagnose Alzheimer's disease.
› Verified 1 days ago
News Archive
Clementia Pharmaceuticals, Inc. announced today the initiation of a Phase 2 extension study of palovarotene in patients with fibrodysplasia ossificans progressiva (FOP), a rare, severely disabling genetic disease characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) and new abnormal bone formation.
Current industry practices for large-scale mammalian cell cultures typically employ a standard platform fed-batch process with fixed volume bolus feeding. Although widely used, these processes are unable to respond to actual nutrient consumption demands from the culture, which can result in accumulation of by-products and depletion of certain nutrients.
ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, today announced that it will be presenting today, at the Annual Meeting of the Congress of Neurological Surgeons in New Orleans, Louisiana at 3:15pm central time, data from its Phase I clinical trial investigating the role that its ICT-107 vaccine may play in increasing patient survival and inhibiting tumor progression in patients with glioblastoma, the most common and most aggressive type of primary brain tumor.
Last week, at the Society for Neuroscience Conference in Washington DC, Neuronetrix announced preliminary results from a clinical study of their COGNISION System to diagnose Alzheimer's disease.
› Verified 1 days ago
Cvs Pharmacy #04274 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 4140 E Joppa Rd, Nottingham, Maryland 21236 Phone: (410) 429-0450 | |
Cvs Pharmacy #16390 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 5230 Campbell Blvd, Nottingham, Maryland 21236 Phone: (410) 933-9680 | |
Wal-mart Pharmacy 10-2045 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 8118 Perry Hills Ct, Nottingham, Maryland 21236 Phone: (410) 882-9943 | |
Giant Pharmacy 2304 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 8905 Belair Road, Nottingham, Maryland 21236 Phone: (410) 856-9870 | |
White Marsh Pharmacy Type: Durable Medical Equipment & Medical Supplies Supplier Location: 4924 Campbell Blvd 120, Nottingham, Maryland 21236 Phone: (443) 384-2500 |